Johnson & Johnson’s Simponi (golimumab) became the latest autoimmune drug FDA has approved for ulcerative colitis, giving the drug additional momentum on its path to becoming a blockbuster.
The inhibitor of tumor necrosis factor is J&J’s second drug approved for the disorder, alongside top seller Remicade (infliximab). Both...